«Previous Article|Table of Contents|Next Article»

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:

2023 07

Page:

1375-1378

Research Field:

Publishing date:

Info

Title:

Progress in the application of liquid biopsy in the diagnosis of glioblastoma

Author(s):

YUAN Kaikun¹; 2; XU Libo¹; 2; LI Qingsong¹; 2

1.The Second Clinical Hospital Affiliated to Harbin Medical University£¬Heilongjiang Harbin 150086£¬China;2.Translational Medicine Research and Cooperation Center of Northern China£¬Heilongjiang Academy of Medical Sciences,Heilongjiang Harbin 150081£¬China.

Keywords:

glioblastoma; circulating biomarkers; liquid biopsy

PACS:

R739.4

DOI:

10.3969/j.issn.1672-4992.2023.07.040

Abstract:

Glioblastoma(GBM) is a central nervous system tumor with extremely aggressive and poor prognosis.At present,the diagnosis of GBM mainly relies on imaging and tissue biopsy.In the era of precision medicine,liquid biopsy,a relatively non-invasive new detection method,has made significant progress in many solid tumors.Compared with traditional laboratory technology,liquid biopsy makes up for the limitations of traditional tissue biopsy that are invasive and cannot be sampled repeatedly.This article will review the application progress of circulating tumor markers such as circulating tumor DNA,microRNA,circulating tumor cells and exosomes in GBM for liquid biopsy.

References:

£Û1£ÝMARENCO-HILLEMBRAND LINA,WIJESEKERA OLINDI,SUAREZ-MEADE PAOLA,et al.Trends in glioblastoma:outcomes over time and type of intervention:a systematic evidence based analysis£ÛJ£Ý.J Neurooncol,2020,147:297-307.
£Û2£Ý¹ú¼ÒÎÀÉú½¡¿µÎ¯Ô±»áÒ½ÕþÒ½¹Ü¾Ö.ÄÔ½ºÖÊÁöÕïÁƹ淶(2018 Äê°æ)£ÛJ£Ý.ÖлªÉñ¾­Íâ¿ÆÔÓÖ¾,2019,35(3):217-239. National Health Commission Medical Administration Bureau.Diagnosis and treatment of gliomas(2018 edition)£ÛJ£Ý.Chinese Journal of Neurosurgery,2019,35(3):217-239.
£Û3£ÝHYGINO DA CRUZ LC,RODRIGUEZ I,DOMINGUES RC,et al.Pseudoprogression and pseudoresponse:imaging challenges in the assessment of posttreatment glioma£ÛJ£Ý.AJNR Am J Neuroradiol,2011,32:1978-1985.
£Û4£ÝMARTINS IVANA,RIBEIRO ILDA PATR¦PCIA,JORGE JOANA,et al.Liquid biopsies:Applications for cancer diagnosis and monitoring£ÛJ£Ý.Genes(Basel),2021,12(3):349.
£Û5£ÝZHAO Xin,SONG Tao,HE Zhoukang,et al.A novel role of cyclinD1 and p16 in clinical pathology and prognosis of childhood medulloblastoma£ÛJ£Ý.Med Oncol,2010,27:985-991.
£Û6£ÝWANG Xiao-Bing,TIAN Xiao-Ying,LI Yang,et al.Elevated expression of macrophage migration inhibitory factor correlates with tumor recurrence and poor prognosis of patients with gliomas£ÛJ£Ý.J Neurooncol,2012,106:43-51.
£Û7£ÝYUAN Xuexia,LIU Deguo,WANG Yanhui,et al.Significance of nuclear magnetic resonance combined with Ki-67 and VEGF detection in the diagnosis and prognosis evaluation of brain glioma£ÛJ£Ý.J BUON,2018,23:410-415.
£Û8£ÝMUR PILAR,RODR¦PGUEZ DE LOPE ¦BNGEL,D¦PAZ-CRESPO FRANCISCO JAVIER,et al.Impact on prognosis of the regional distribution of MGMT methylation with respect to the CpG island methylator phenotype and age in glioma patients£ÛJ£Ý.J Neurooncol,2015,122:441-450.
£Û9£ÝPICCA ALBERTO,BERZERO GIULIA,DI STEFANO ANNA LUISA,et al.The clinical use of IDH1 and IDH2 mutations in gliomas£ÛJ£Ý.Expert Rev Mol Diagn,2018,18:1041-1051.
£Û10£ÝLIU Yang,LI Yun-ming,TIAN Rui-feng,et al.The expression and significance of HIF-1alpha and GLUT-3 in glioma£ÛJ£Ý.Brain Res,2009,1304:149-154.
£Û11£ÝVUONG HUY GIA,ALTIBI AHMED MA,DUONG UYEN NP,et al.TERT promoter mutation and its interaction with IDH mutations in glioma:Combined TERT promoter and IDH mutations stratifies lower-grade glioma into distinct survival subgroups-A meta-analysis of aggregate data£ÛJ£Ý.Crit Rev Oncol Hematol,2017,120:1-9.
£Û12£ÝSIEGAL TALI.Clinical impact of molecular biomarkers in gliomas£ÛJ£Ý.J Clin Neurosci,2015,22:437-444.
£Û13£ÝIGNATIADIS MICHAIL,LEE MARK,JEFFREY STEFANIE S.Circulating tumor cells and circulating tumor DNA:Challenges and opportunities on the path to clinical utility£ÛJ£Ý.Clin Cancer Res,2015,21:4786-4800.
£Û14£ÝBETTEGOWDA CHETAN,SAUSEN MARK,LEARY REBECCA J,et al.Detection of circulating tumor DNA in early- and late-stage human malignancies£ÛJ£Ý.Sci Transl Med,2014,6:224ra24.
£Û15£ÝPICCIONI DAVID E,ACHROL ACHAL SINGH,KIEDROWSKI LESLI A,et al.Analysis of cell-free circulating tumor DNA in 419 patients with glioblastoma and other primary brain tumors£ÛJ£Ý.CNS Oncol,2019,8:CNS34.
£Û16£ÝMILLER ALEXANDRA M,SHAH RONAK H,PENTSOVA ELENA I,et al.Tracking tumour evolution in glioma through liquid biopsies of cerebrospinal fluid£ÛJ£Ý.Nature,2019,565:654-658.
£Û17£ÝWANG Zheng,JIANG Wei,WANG Yahong,et al.MGMT promoter methylation in serum and cerebrospinal fluid as a tumor-specific biomarker of glioma£ÛJ£Ý.Biomed Rep,2015,3:543-548.
£Û18£ÝFARIA GISELLE,SILVA EMANUELLE,DA FONSECA CLOVIS,et al.Circulating cell-free DNA as a prognostic and molecular marker for patients with brain tumors under perillyl alcohol-based therapy£ÛJ£Ý.Int J Mol Sci,2018,19:undefined.
£Û19£ÝWANG JOANNA,BETTEGOWDA CHETAN.Applications of DNA-based liquid biopsy for central nervous system neoplasms£ÛJ£Ý.J Mol Diagn,2017,19:24-34.
£Û20£ÝGYURIS A,NAVARRETE-PEREA J,JO A,et al.Physical and molecular landscapes of mouse glioma extracellular vesicles define heterogeneity£ÛJ£Ý.Cell Rep£¬2019£¬27(13):3972-3987.
£Û21£ÝSORBER L,ZWAENEPOEL K,JACOBS J,et al.Circulating cell-free DNA and RNA analysis as liquid biopsy:optimal centrifugation protocol£ÛJ£Ý.Cancers(Basel)£¬2019£¬11(4):E458.
£Û22£ÝOSTHEIM P,TICHY A,SIRAK I,et al.Overcoming challenges in human saliva gene expression measurements£ÛJ£Ý.Sci Rep,2020,10(1):11147.
£Û23£ÝITA MI,WANG JH,TOULOUSE A,et al.The utility of plasma circulating cell-free messenger RNA as a biomarker of glioma:a pilot study£ÛJ£Ý.Acta Neurochir(Wien),2022,164(3):723-735.
£Û24£ÝRINCON-TORROELLA J,KHELA H,BETTEGOWDA A,et al.Biomarkers and focused ultrasound:the future of liquid biopsy for brain tumor patients£ÛJ£Ý.J Neurooncol,2022,156(1):33-48.
£Û25£ÝFLOYD DESIREE,PUROW BENJAMIN.Micro-masters of glioblastoma biology and therapy:increasingly recognized roles for microRNAs£ÛJ£Ý.Neuro-oncology,2014,16:622-627.
£Û26£ÝZHOU Q,LIU J,QUAN J,et al.MicroRNAs as potential biomarkers for the diagnosis of glioma:A systematic review and meta-analysis£ÛJ£Ý.Cancer Sci,2018,109(9):2651-2659.
£Û27£ÝTORAIH EA,ALY NM,ABDALLAH HY,et al.MicroRNA-target cross-talks:Key players in glioblastoma multiforme£ÛJ£Ý.Tumor Biology,2017,39(11):1010428317726842.
£Û28£ÝZHAO H,SHEN J,HODGES TR,et al.Serum microRNA profiling in patients with glioblastoma:a survival analysis£ÛJ£Ý.Mol Cancer,2017,16(1):59.
£Û29£ÝXIONG Xuehua,DENG Jianping,ZENG Chun,et al.MicroRNA-141 is a tumor regulator and prognostic biomarker in human glioblastoma£ÛJ£Ý.Oncol Lett,2017,14:4455-4460.
£Û30£ÝCHEN J,YANG L,WANG X.Reduced circulating microRNA-203 predicts poor prognosis for glioblastoma£ÛJ£Ý.Cancer Biomarkers,2017,20(4):521-526.
£Û31£ÝLORENTE D,OLMOS D,MATEO J,et al.Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts£ÛJ£Ý.Ann Oncol,2018,29:1554-1560.
£Û32£ÝTONG B,XU Y,ZHAO J,et al.Prognostic significance of circulating tumor cells in non-small cell lung cancer patients undergoing chemotherapy£ÛJ£Ý.Oncotarget,2017,8(49):86615-86624.
£Û33£ÝGKOUNTELA SOFIA,CASTRO-GINER FRANCESC,SZCZERBA BARBARA MARIA,et al.Circulating tumor cell clustering shapes DNA methylation to enable metastasis seeding£ÛJ£Ý.Cell,2019,176:98-112.
£Û34£ÝGAO F,CUI Y,SUI D,et al.Circulating tumor cell is a common property of brain glioma and promotes the monitoring system£ÛJ£Ý.Oncotarget,2016,7(44):71330-71340.
£Û35£ÝMALARA N,GUZZI G,MIGNOGNA C,et al.Non-invasive real-time biopsy of intracranial lesions using short time expanded circulating tumor cells on glass slide:report of two cases£ÛJ£Ý.BMC Neurol,2016,16:127.
£Û36£ÝLE RHUN E,SEOANE J,SALZET M,et al.Liquid biopsies for diagnosing and monitoring primary tumors of the central nervous system£ÛJ£Ý.Cancer Letters,2020,480:24-28.
£Û37£ÝHALLAL SUSANNAH,EBRAHIMKHANI SAEIDEH,SHIVALINGAM BRINDHA,et al.The emerging clinical potential of circulating extracellular vesicles for non-invasive glioma diagnosis and disease monitoring£ÛJ£Ý.Brain Tumor Pathol,2019,36:29-39.
£Û38£ÝOSTI DANIELA,DEL BENE MASSIMILIANO,RAPPA GERMANA,et al.Clinical significance of extracellular vesicles in plasma from glioblastoma patients£ÛJ£Ý.Clin Cancer Res,2019,25:266-276.
£Û39£ÝINDIRA CHANDRAN VINEESH,WELINDER CHARLOTTE,M¦@NSSON ANN-SOFIE,et al.Ultrasensitive immunoprofiling of plasma extracellular vesicles identifies syndecan-1 as a potential tool for minimally invasive diagnosis of glioma£ÛJ£Ý.Clin Cancer Res,2019,25:3115-3127.
£Û40£ÝLUCERO ROCCO,ZAPPULLI VALENTINA,SAMMARCO ALESSANDRO,et al.Glioma-derived miRNA-containing extracellular vesicles induce angiogenesis by reprogramming brain endothelial cells£ÛJ£Ý.Cell Rep,2020,30:2065-2074.
£Û41£ÝMANDA SASIDHAR VENKATA,KATARIA YOGESH,TATIREDDY BABUL REDDY,et al.Exosomes as a biomarker platform for detecting epidermal growth factor receptor-positive high-grade gliomas£ÛJ£Ý.J Neurosurg,2018,128:1091-1101.

Memo

Memo:

-

Common functions

Last Update: 2023-02-28